2.68
Schlusskurs vom Vortag:
$2.68
Offen:
$2.7
24-Stunden-Volumen:
21,729
Relative Volume:
0.06
Marktkapitalisierung:
$4.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.0628
EPS:
-42.6996
Netto-Cashflow:
$-4.67M
1W Leistung:
+1.52%
1M Leistung:
+21.27%
6M Leistung:
-93.50%
1J Leistung:
-95.14%
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CMND
Clearmind Medicine Inc
|
2.68 | 4.02M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal - MSN
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - The Manila Times
Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2025 - Quiver Quantitative
Clearmind Medicine: Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk - TradingView
Will Clearmind Medicine Inc. stock deliver shareholder valueDay Trade & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine (NASDAQ:CMND) Shares Up 0.4% – What’s Next? - Defense World
Clearmind completes treatment for second cohort in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind announces completion of treatment for second cohort in CMND-100 trial - TipRanks
Clearmind Completes Treatment In 2nd Cohort Of CMND-100 Phase I/IIa Trial In Alcohol Use Disorder - Nasdaq
Clearmind completes treatment for second cohort in AUD drug trial - Investing.com
Clearmind Medicine IncTopline results from second cohort of CMND-100 expected in coming months - marketscreener.com
Clearmind Medicine Inc. Completes Treatment for Second Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - The Manila Times
6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan
Will Clearmind Medicine Inc. outperform tech stocks2025 Trading Recap & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Aug Final Week: Does Clearmind Medicine Inc stock trade at a discount to peersJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Risk On: Is Clearmind Medicine Inc a potential multi bagger2025 Valuation Update & Safe Entry Zone Tips - baoquankhu1.vn
Why Clearmind Medicine Inc. stock remains on buy listsTrail vs Road Selection & compare fit, width, and feel - Улправда
Published on: 2026-01-09 01:57:04 - Улправда
Does Clearmind Medicine Inc. (CWY0) stock trade below intrinsic valueQuarterly Investment Review & Scalable Portfolio Growth Methods - Улправда
Will Clearmind Medicine Inc. stock benefit from AI adoptionStock Buy Signals & Target Triple-Digit Stock Opportunities - ulpravda.ru
Surprises Report: Why Clearmind Medicine Inc stock is recommended by analystsChart Signals & Safe Swing Trade Setups - Bộ Nội Vụ
How geopolitical tensions affect Clearmind Medicine Inc. stock2026 world cup usa national team group stage defensive leaders possession football match prediction insights - Улправда
Why retail traders accumulate Clearmind Medicine Inc. (CWY0) stockStop Loss Placement Tips & Build Wealth With Zero-Cost Tools - bollywoodhelpline.com
Portfolio Shifts: Why Clearmind Medicine Inc stock is recommended by analystsRate Cut & Reliable Price Action Trade Plans - moha.gov.vn
Clearmind Medicine (CMND) Stock Analysis Report | Financials & Insights - Benzinga España
Clearmind Medicine Announces the Notice of an International Patent App... - Moscow-Pullman Daily News
Clearmind regains Nasdaq compliance as shares maintain $1 minimum By Investing.com - Investing.com Nigeria
Clearmind regains Nasdaq compliance as shares maintain $1 minimum - Investing.com India
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule - MarketScreener
Clearmind Medicine regains compliance with Nasdaq minimum bid price rule - TipRanks
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Requirements | CMND Stock News - Quiver Quantitative
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Clearmind Medicine highlights key 2025 achievements - MSN
Clearmind advances AUD treatment as phase I/IIa trial progresses By Investing.com - Investing.com Australia
Clearmind advances AUD treatment as phase I/IIa trial progresses - Investing.com
Clearmind Medicine Inc. Reflects on Major Progress in 2025 Clinical Trials for CMND-100 Targeting Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth - Yahoo Finance
Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial - MSN
San Gabriel Valley Tribune - FinancialContent
Cash from operating activities of Clearmind Medicine Inc. – MUN:CWY - TradingView — Track All Markets
Trading Recap: How strong is Clearmind Medicine Inc. stock balance sheetJuly 2025 Selloffs & Weekly Setup with ROI Potential - moha.gov.vn
How interest rate cuts could boost Clearmind Medicine Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - Улправда
Clearmind Medicine Inc. (NASDAQ: CMND)Share Price - intelligentinvestor.com.au
Published on: 2025-12-19 05:54:25 - Улправда
Pretax income of Clearmind Medicine Inc. – LS:A41YK5 - TradingView — Track All Markets
Clearmind Medicine completes second cohort enrollment in Phase I/IIa AUD trial - MSN
Free float of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):